Company Overview of EnGeneIC Ltd.
EnGeneIC Ltd., a bioscience company, develops and commercializes novel concepts in the targeted delivery of chemotherapeutics for cancer drugs in-vivo. The company’s drug/siRNA delivery vehicles offer a range of choices for optimizing the delivery of clinically meaningful drug and siRNA doses to target cancer cells in-vivo. It serves customers in Australia, Singapore, Japan, and India. The company was incorporated in 2000 and is based in Lane Cove West, Australia.
2/25 Sirius Road
Lane Cove West, NSW 2066
Founded in 2000
Key Executives for EnGeneIC Ltd.
Co-Managing Director and Director
Founder, Co-Managing Director and Director
Compensation as of Fiscal Year 2014.
EnGeneIC Ltd. Key Developments
EnGeneIC Ltd. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 09:30 AM
Feb 4 15
EnGeneIC Ltd. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 09:30 AM. Venue: The Waldorf Astoria, New York, New York, United States. Speakers: Himanshu Brahmbhatt, Co-Managing Director and Director, Jennifer A. MacDiarmid, Founder, Co-Managing Director and Director.
EnGeneIC Ltd. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 08:30 AM
Dec 18 14
EnGeneIC Ltd. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 08:30 AM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.
EnGeneIC Ltd. Unveils Clinical Development Strategy for EDV Nanocell Technology
Jun 24 14
EnGeneIC Ltd. announced plans to move forward with a Phase 2a clinical trial in the U.S. using its formulation of EGFR-targeted, EDV nanocells packaged with doxorubicin for the treatment of recurrent glioblastoma (GBM), a common and aggressive type of brain tumor. In June 2014, EnGeneIC completed a Phase 1 trial in recurrent glioma in Australia and now plans to submit an IND and commence the U.S. clinical program in early 2015. EnGeneIC's bacterially-derived EDV nanocells are a powerful nanoparticle drug delivery system designed to directly target and effectively kill tumor cells with minimal toxicity, while at the same time stimulate the immune system's natural anti-tumor response. Intravenously injected EDV nanocells exit the leaky vascular system only within tumors and attach to cancer cells via a specially designed, targeted bi-specific antibody. Once attached, the nanocell is able to enter the tumor cell and deliver a drug payload of up to one million drug molecules per nanocell. In parallel, the bacterial cell wall of the nanocells stimulates key components of the immune system, which are then activated to seek out and destroy cancer cells.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 12, 2014